These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21421804)

  • 1. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
    Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D
    Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.
    Kharbanda A; Rajabi H; Jin C; Tchaicha J; Kikuchi E; Wong KK; Kufe D
    Clin Cancer Res; 2014 Nov; 20(21):5423-34. PubMed ID: 25189483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
    Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D
    Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
    Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
    Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
    Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
    Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
    Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
    Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
    Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
    Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer.
    Li XQ; Cheng XJ; Wu J; Wu KF; Liu T
    Cell Mol Biol Lett; 2024 Apr; 29(1):58. PubMed ID: 38649803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression.
    Li L; Wang S; Zheng F; Wu W; Hann SS
    J Ethnopharmacol; 2016 Dec; 194():918-929. PubMed ID: 27989877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.
    Alam M; Rajabi H; Ahmad R; Jin C; Kufe D
    Oncotarget; 2014 May; 5(9):2622-34. PubMed ID: 24770886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.
    Zhang Z; Zhang M; Liu H; Yin W
    J Cell Biochem; 2019 Jan; 120(1):756-767. PubMed ID: 30145802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Bouillez A; Rajabi H; Pitroda S; Jin C; Alam M; Kharbanda A; Tagde A; Wong KK; Kufe D
    Cancer Res; 2016 Mar; 76(6):1538-48. PubMed ID: 26833129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MUC1-C regulates metabolism by AKT pathway in esophageal squamous cell carcinoma.
    GongSun X; Zhao Y; Jiang B; Xin Z; Shi M; Song L; Qin Q; Wang Q; Liu X
    J Cell Physiol; 2019 Jul; 234(7):12019-12028. PubMed ID: 30523643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sialidase NEU1 directly interacts with the juxtamembranous segment of the cytoplasmic domain of mucin-1 to inhibit downstream PI3K-Akt signaling.
    Hyun SW; Imamura A; Ishida H; Piepenbrink KH; Goldblum SE; Lillehoj EP
    J Biol Chem; 2021 Nov; 297(5):101337. PubMed ID: 34688655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
    Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
    Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteoloside induces G
    Zhou M; Shen S; Zhao X; Gong X
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
    Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.
    Yao M; Zhang W; Zhang Q; Xing L; Xu A; Liu Q; Cui B
    Lung; 2011 Dec; 189(6):453-60. PubMed ID: 21959954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
    Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
    PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.